In June 2022, we created and published “Meet AmacaThera and learn about our novel hydrogel platform,” a one-minute animation that outlines its approach to drug development.
Watch our platform animation below.
AmacaThera’s goal is to revolutionize the range of treatment options available to patients in multiple areas using multiple therapeutic agents, such as small molecules, antibodies, proteins or peptides.
The company’s hydrogel platform could be used to deliver long-lasting treatments with a variety of therapeutic applications, including post-surgical pain management, cancer, and other targeted areas that require therapeutic care, such as the brain.
AmacaThera is a clinical-stage biotechnology company developing a novel drug delivery platform to improve patient outcomes across multiple therapeutic areas, including post‑surgical pain management, cancer and other hard‑to‑reach target areas.
New study setting the stage for non-opioid analgesic in post-surgical pain management
AmacaThera collaborates with University Health Network to evaluate the economic impact of post-surgical opioid use. They are developing non-opioid analgesic, AMT-143, aiming to reduce the reliance on opioid medications.Read more
AmacaThera Doses First Subjects in Phase 1 Clinical Trial for AmacaGel™ Therapeutic Platform
AmacaThera Inc today announced that the first subjects have been dosed in the company's Phase 1 first-in-human clinical investigation of the safety of AmacaGel™.Read more
AmacaThera’s Lung Cancer Applications Recognized in QuickFire Challenge
AmacaThera has received grant funding from the Innovations for Vets QuickFire Challenge: Lung Cancer & Physical Trauma.Read more